Alkem Laboratories
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Alkem Laboratories is navigating a complex landscape characterized by strong core performance in chronic therapies and strategic investments in new growth engines, particularly in biosimilars and MedTech. Management's disciplined approach, focusing on branded formulations in India while addressing challenges in the U.S. market, underpins Vista's forecast of stable margins and moderate revenue growth. The company's recent acquisition of Occlutech and ongoing regulatory remediation efforts are expected to enhance its competitive position, although the trade generics segment faces headwinds from increased competition. Vista anticipates a high single-digit revenue growth in the U.S. and higher teens in international markets, supported by new product launches and a favorable currency environment. However, rising input costs and pricing pressures in key markets could temper profitability. Over the next 12-24 months, Alkem's focus on operational efficiency and strategic expansion will be critical, with opportunities in biosimilars and MedTech potentially driving future growth. Key watchpoints include the successful integration of acquisitions and the impact of regulatory challenges on revenue stability
Why We Like This Stock
- Strong performance in chronic therapies and successful product launches, such as semaglutide, are expected to drive revenue growth
- Strategic investments in biosimilars and MedTech, including the acquisition of Occlutech, are anticipated to unlock new revenue streams
- Management's focus on operational efficiency and regulatory compliance is likely to support stable margins despite external pressures
Things To Watch Out For
- Increased competition in the trade generics segment poses a near-term headwind to revenue growth
- Rising input costs and pricing pressures in the U.S. market may challenge profit margins
- Execution risks related to client acquisition and capacity expansion could impact the success of new growth initiatives
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 12,668 | 12,965 | 14,712 | 15,211 | 16,767 |
| Profit Before Tax (Cr.) | 2,148 | 2,522 | 3,046 | 3,017 | 3,388 |
| PBT Margin | 17.0% | 19.5% | 20.7% | 19.8% | 20.2% |
| Net Profit (Cr.) | 1,699 | 1,998 | 2,386 | 2,367 | 2,604 |
| Earnings Per Share | 140.8 | 163.0 | 195.5 | 193.9 | 217.8 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Investec | ▲ Buy | 6,500 | 17-Aug-2026 |
| JPMorgan | ► Hold | 6,100 | 17-Aug-2026 |
| Macguire | ▼ Underperform | 4,900 | 17-Aug-2026 |
| Motilal Oswal | ► Neutral | 5,770 | 16-Aug-2026 |
| Choice Equity | ► Hold | 5,775 | 29-May-2026 |
| HDFC Securities | ► Add | 6,230 | 29-May-2026 |
| ICICI Securities | ▲ Buy | 6,850 | 29-May-2026 |
| Jeffries | ▲ Buy | 6,500 | 29-May-2026 |
| Nomura | ▲ Buy | 6,890 | 29-May-2026 |
Company Overview
Show Company Profile
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products in therapeutic areas comprising anti infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology, central nervous system, anti-diabetic, iron deficiency, pain management, and urology, as well as vitamins, minerals, and nutrients. It also provides cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. Alkem Laboratories Limited was incorporated in 1973 and is based in Mumbai, India.